机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai[2]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou[3]Department of Internal Medicine-Oncology, Jilin Cancer Hospital, Changchun[4]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai[5]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu四川大学华西医院[6]Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin[7]Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan[8]Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha[9]Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou浙江省肿瘤医院[10]Department of Medical Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing[11]Department of Respiratory Medicine, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou河南省肿瘤医院[12]Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou[13]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an[14]Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing[15]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan华中科技大学同济医学院附属协和医院[16]Department of Oncology, Xinqiao Hospital, The Army Medical University, Chongqing, China
This work was supported in part by grants from the
Shanghai ‘Rising Stars of Medical Talent’ Youth Development
Program, National Nature Science Foundation of
China [grant numbers 82141101, 81703020], Shanghai
Multidisciplinary Cooperative Project for Diagnosis and
Treatment of Major Diseases (no grant number), and Key
Clinical Project Development Program of Shanghai (no grant
number).
第一作者机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai
通讯作者：
通讯机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai[*1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Yangpu District, Shanghai 200433, China.
推荐引用方式(GB/T 7714)：
Zhou F,Yang Y,Zhang L,et al.Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors[J].ESMO OPEN.2023,8(3):doi:10.1016/j.esmoop.2023.101560.
APA：
Zhou F,Yang Y,Zhang L,Cheng Y,Han B...&Zhou C.(2023).Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.ESMO OPEN,8,(3)
MLA：
Zhou F,et al."Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors".ESMO OPEN 8..3(2023)
医学